{"entity":{"id":"nct05883644","kind":"trial","name":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","aka":["SIERRA"],"tldr":"A phase 3 trial of Durvalumab, Tremelimumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) is a phase 3 interventional study registered as NCT05883644 by AstraZeneca, with 111 participants enrolled, started 2023-06-27 and due to reach its primary completion in 2026-03-30. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Advanced Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05883644","url":"https://clinicaltrials.gov/study/NCT05883644"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc","hcc-advanced"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","tremelimumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05883644","phase":"3","setting":"A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)","sponsor":"AstraZeneca","participation":[{"nct":"NCT05883644","source":"https://clinicaltrials.gov/study/NCT05883644","fetchedAt":"2026-10-07T16:53:59.307Z","studySha256":"4f9cea02fe973d7951c48dc8ffc2610670cca71c1c8572e84d74a41982c3d0fe","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":111,"enrolmentType":"ACTUAL","siteCount":40,"recruitingSiteCount":0,"countries":["France","Germany","Hong Kong","Italy","Japan","Singapore","South Korea","Spain","United States","Vietnam"]}],"started":"2023-06-27","startedType":"actual","enrolled":111,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05883644/","neighbours":{"cancer":[{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}